Incentive mechanism and implications of orphan drug market in the United States
10.3969/j.issn.1674-2982.2016.02.008
- VernacularTitle:美国罕用药市场的激励机制及其启示
- Author:
Qilin ZHANG
;
Xinlu SONG
- Publication Type:Journal Article
- Keywords:
The United States;
Rare disease;
Orphan drug;
Incentive mechanism
- From:
Chinese Journal of Health Policy
2016;9(2):36-44
- CountryChina
- Language:Chinese
-
Abstract:
Serious market failure, as a result of insufficient incentive, exists in the orphan drugs market. Through legislation, the United States designed and established its owns systematic and linked orphan drugs incentive mechanism, which direct sat research, definition, clinical trials and approval of orphan drugs, so as to change the supply and demand status of orphan drugs. Such incentive mechanism erables the United States possess the most ap-proved orphan drugs in the world, and effectively relieves the problem of market failure of the orphan drugs. The ex-perience of the United States provides beneficial reference for the establishment and positive development of orphan drugs incentive mechanism in China.
